210 Participants Needed
Dana-Farber Cancer Institute logo

Cardiac Screening for Hodgkin's Lymphoma Survivors

Recruiting at 1 trial location
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Dana-Farber Cancer Institute
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Echo/Stress Echo for cardiac screening in Hodgkin's Lymphoma survivors?

Research shows that stress echocardiography can reveal heart abnormalities in cancer survivors who have undergone treatments like chemotherapy, which can affect the heart. This suggests that Echo/Stress Echo might be useful in detecting heart issues early in Hodgkin's Lymphoma survivors, helping to manage potential heart problems before they become serious.12345

Is cardiac screening safe for Hodgkin's Lymphoma survivors?

Cardiac screening methods like echocardiograms (heart ultrasound) and stress echocardiograms (heart ultrasound during exercise) are generally safe for humans. These tests are used to monitor heart health, especially in Hodgkin's Lymphoma survivors who may have increased risks of heart issues due to past treatments.13467

How does the Echo/Stress Echo treatment differ from other treatments for cardiac screening in Hodgkin's Lymphoma survivors?

Echo/Stress Echo is a non-invasive screening method that uses ultrasound to assess heart function and detect potential heart issues, which is particularly important for Hodgkin's Lymphoma survivors who are at increased risk of heart problems due to past radiation and chemotherapy treatments. This approach is unique because it focuses on early detection of heart issues, allowing for timely intervention and management of cardiovascular risks.13689

What is the purpose of this trial?

The main purpose of this study is to determine if it is possible to put into practice a cardiac screening program for survivors of Hodgkin's disease. In this study, we would also like to screen for cardiac risk factors that can be modified either through life-style changes or medications, to uncover significant abnormal heart findings in which treatments may be needed, and to see if there is a link between cardiac health and quality of life.

Research Team

AK

Andrea K. Ng

Principal Investigator

Dana-Farber Cancer Institute

Eligibility Criteria

This trial is for survivors of Hodgkin's disease who were treated with chest radiation at Brigham and Women's Hospital or Dana-Farber Cancer Institute, are over 15 years old, have been in remission for more than a year, and it has been five or more years since their initial treatment.

Inclusion Criteria

I have been free from cancer for more than a year.
I received treatment for Hodgkin's disease with chest radiation at Brigham and Women's Hospital or Dana-Farber Cancer Institute.
I am 15 years old or older.
See 1 more

Exclusion Criteria

My condition worsened within a year of treatment.
Less than 5 years out from initial treatment
Patients treated for Hodgkin's disease outside of Brigham and Women's Hospital or Dana-Farber Cancer Institute
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1 day
1 visit (in-person)

Cardiac Screening

Participants meet with a study cardiologist and undergo cardiac risk factors screening, resting and stress echocardiogram

1 day
1 visit (in-person)

Follow-up

Participants are monitored for cardiac health and quality of life, with repeat screenings every 18 months to 3 years depending on time since initial treatment

3 years
Multiple visits (in-person)

Treatment Details

Interventions

  • Echo/Stress Echo
Trial Overview The study aims to establish a heart screening program for Hodgkin's disease survivors. It involves checking the heart using echo/stress echo tests to identify potential risks and improve quality of life through lifestyle changes or medication if needed.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Cardiac screeningExperimental Treatment1 Intervention
Interventions: Participants will * meet with study cardiologist * undergo cardiac risk factors screening * undergo resting and stress echocardiogram (echo and stress echo)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Dana-Farber Cancer Institute

Lead Sponsor

Trials
1,128
Recruited
382,000+

Brigham and Women's Hospital

Collaborator

Trials
1,694
Recruited
14,790,000+

Findings from Research

A study involving 191 childhood cancer survivors showed that the handheld mHealth platform (Vivio) accurately assessed cardiac function, with results closely matching those from cardiac magnetic resonance imaging (CMR), indicating its potential for effective real-time monitoring.
In contrast, traditional echocardiography significantly overestimated left ventricular ejection fraction (EF) and had poor sensitivity for detecting cardiac dysfunction, highlighting the advantages of using Vivio for better identification of at-risk patients.
Accuracy of a Novel Handheld Wireless Platform for Detection of Cardiac Dysfunction in Anthracycline-Exposed Survivors of Childhood Cancer.Armenian, SH., Rinderknecht, D., Au, K., et al.[2019]
In a study of 77 childhood cancer survivors (CCSs) who were at least 1 year post-chemotherapy, the prevalence of abnormal left ventricular global longitudinal strain (GLS) increased with exercise stress, indicating some CCSs may have impaired cardiac adaptation during physical activity.
Despite the increased prevalence of abnormal GLS under stress, CCSs showed similar average GLS and strain values compared to healthy controls, suggesting that significant cardiac dysfunction may not be evident early after treatment, particularly in those treated with high-dose anthracyclines or diagnosed before age 5.
Left Ventricular Strain Analysis During Submaximal Semisupine Bicycle Exercise Stress Echocardiography in Childhood Cancer Survivors.von Scheidt, F., Pleyer, C., Kiesler, V., et al.[2022]

References

Late Cardiological Sequelae and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi. [2022]
Accuracy of a Novel Handheld Wireless Platform for Detection of Cardiac Dysfunction in Anthracycline-Exposed Survivors of Childhood Cancer. [2019]
Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study. [2019]
Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study. [2010]
Left Ventricular Strain Analysis During Submaximal Semisupine Bicycle Exercise Stress Echocardiography in Childhood Cancer Survivors. [2022]
Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. [2011]
A pilot investigation on impact of participation in a long-term follow-up clinic (LTFU) on breast cancer and cardiovascular screening among women who received chest radiation for Hodgkin lymphoma. [2019]
Screening Hodgkin lymphoma survivors for radiotherapy induced cardiovascular disease. [2011]
Is screening for abnormal ECG patterns justified in long-term follow-up of childhood cancer survivors treated with anthracyclines? [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security